

TRANSACTIONS GRANTED EARLY TERMINATION BETWEEN: 06/23/97 AND 07/04/97—Continued

Name of acquiring person, name of acquired person, name of acquired entity	PMN No.	Date terminated
Gerald W. Schwartz, Hewlett-Packard Company, Hewlett-Packard Company (Computer Systems Manufacturing)	97-2499	07/01/97
John M. Rudey, Ochoco Lumber Company, Ochoco Lumber Company	97-2543	07/01/97
MicroAge, Inc., Steven R. Becker, KNB, Inc.	97-2551	07/01/97
Gordon S. Lang, SEDA Specialty Packaging Corp., Specialty Packaging Corp.	97-2561	07/01/97
Lancaster Colony Corporation, Chatham Village Foods, Inc., Chatham Village Foods, Inc.	97-2585	07/01/97
Brunswick Corporation, Mancuso/Equity Partnership No. 2, L.P., Life Fitness	97-2386	07/02/97
Pechiney, Financiere Techpack, Financiere Techpack	97-2414	07/02/97
David Vaccarezza, United Waste Systems, Inc., United Waste Systems, Inc.	97-2448	07/02/97
United Waste Systems, Inc., David Vaccarezza, California Waste Recovery Systems, Inc.	97-2449	07/02/97
Harman International Industries, Inc., Michael J. Oslac, Oxford International, Ltd.	97-2537	07/02/97
PacificCorp, U.S. West, Inc., U.S. West Communications, Inc.	97-2547	07/02/97
Trico Marine Services, Inc., Otto Candies, Inc., Otto Candies, Inc.	97-2548	07/02/97
U.S. Office Products Company, Mail Boxes Etc., Mail Boxes Etc.	97-2552	07/02/97
Lowell L. Paxson, Landmark Communications, Inc., The Travel Channel, Inc.	97-2556	07/02/97
Gannett Co., Inc., Army Times Publishing Company, Army Times Publishing Company	97-2565	07/02/97
Usinor, Macsteel Services Centers USA, Inc. (NEWCO), Macsteel Service Centers USA, Inc. (NEWCO)	97-2572	07/02/97
The Second Dave Samson Trust, Macsteel Service Centers USA, Inc. (NEWCO), Macsteel Service Centers USA, Inc. (NEWCO)	97-2575	07/02/97
Nextel Communications, Inc., Potomac Corporation, Crescent Communications	97-2591	07/02/97
Jon M. Huntsman, Rexene Corporation, Rexene Corporation	97-2489	07/03/97
KMart Corporation, Venture Stores, Inc., Venture Stores, Inc.	97-2589	07/03/97

FOR FURTHER INFORMATION CONTACT:

Sandra M. Peay or Parcellena P. Fielding, Contact Representatives, Federal Trade Commission, Premerger Notification Office, Bureau of Competition, Room 303, Washington, D.C. 20580, (202) 326-3100.

By Direction of the Commission.

Donald S. Clark,
Secretary.

[FR Doc. 97-18989 Filed 7-17-97; 8:45 am]

BILLING CODE 6750-01-M

FEDERAL TRADE COMMISSION**Report of the Tar, Nicotine, and Carbon Monoxide Yield of 1206 Varieties of Domestic Cigarettes for the Year 1994**

ACTION: Notice.

SUMMARY: The Federal Trade Commission publishes the Report of the Tar, Nicotine, and Carbon Monoxide Yield of 1206 Varieties of Domestic Cigarettes.

DATE: July 18, 1997.

ADDRESSES: Copies of the full report are available from the FTC's Public Reference Branch, Room 130, 6th St. and Pennsylvania Ave., N.W., Washington, D.C. 20580. (202) 326-3222.

FOR FURTHER INFORMATION CONTACT:

Phillip S. Priesman, Attorney, Federal Trade Commission, Bureau of Consumer Protection, 6th St. and Pennsylvania Ave., N.W., Washington, D.C. 20580. Telephone (202) 326-2484.

SUPPLEMENTARY INFORMATION: These are the most recent test results of the tar, nicotine, and carbon monoxide levels of

the smoke of domestic cigarettes reported by the FTC. This Report contains data on 1206 varieties of cigarettes manufactured and sold in the United States in 1994. The Tobacco Institute Testing Laboratory (TITL), a private laboratory operated by the cigarette industry, conducted the tar, nicotine, and carbon monoxide testing for the widely-available domestic cigarette varieties. This testing was conducted under the review of a representative of the FTC through periodic unannounced inspections. TITL provided the results to the respective cigarette companies. The companies provided the data generated by TITL regarding their own brands to the FTC in response to compulsory process issued by the Commission. Cigarette smoke from generic, private label, and not-widely-available cigarettes was not tested by TITL, but was tested by the cigarette companies and provided under compulsory process to the FTC. The methodology, processes, and procedures that the companies and TITL employed are required to be the same as those the Commission has followed in the past.

In October 1996, the National Cancer Institute (NCI) published the 7th monograph in its smoking and tobacco control series: "The FTC Cigarette Test Method for Determining Tar, Nicotine, and Carbon Monoxide Yields of U.S. Cigarettes: Report of the NCI Expert Committee." In light of the concerns raised by the NCI conferees about the current system, the Commission is giving careful consideration to possible changes in the test method.

By direction of the Commission.

Donald S. Clark,
Secretary.

[FR Doc. 97-18990 Filed 7-17-97; 8:45 am]

BILLING CODE 6750-01-M

DEPARTMENT OF HEALTH AND HUMAN SERVICES**National Vaccine Injury Compensation Program: Public Hearing Regarding Vaccine Administration Guidelines**

AGENCY: Health Resources and Services Administration, HHS.

ACTION: Notice of public hearing.

SUMMARY: This document announces a public hearing to receive information and views on the section entitled, "Guidelines" in the Notice of Proposed Rulemaking (NPRM) entitled "National Vaccine Injury Compensation Program: Revisions and Additions to the Vaccine Injury Table-II."

DATES: The public hearing will be held on September 11, 1997, at 1:00 p.m. Requests to testify should be submitted by August 28, 1997.

ADDRESSES: The public hearing will be held in Conference Rooms D and E in the Parklawn Building, 5600 Fishers Lane, Rockville, Maryland 20857.

FOR FURTHER INFORMATION CONTACT: Mr. Thomas E. Balbier, Jr., Director, Division of Vaccine Injury Compensation, at (301) 443-6593.

SUPPLEMENTARY INFORMATION: The National Childhood Vaccine Injury Act

of 1986 (Pub. L. 99-660) created a system of no-fault compensation for certain individuals who have been injured by specific childhood vaccines: namely, diphtheria, tetanus, pertussis, polio, measles, mumps or rubella vaccines. Section 313 of Public Law 99-660 called for the Secretary of Health and Human Services to arrange for a study of the risks associated with certain of these vaccines and to establish guidelines based on the results of the 313 study "respecting the administration" of the vaccines that were reviewed, which guidelines shall include:

- (i) The circumstances under which any such vaccine should not be administered;
- (ii) The circumstances under which administration of any such vaccine should be delayed beyond its usual time of administration; and
- (iii) The groups, categories, or characteristics of potential recipients of such vaccine who may be at significantly higher risk of major adverse reactions to such vaccine than the general population of potential recipients.

We have examined the recommendations of the Advisory Committee on Immunization Practices (ACIP) of the Centers for Disease Control and Prevention (CDC), as set forth in the Morbidity and Mortality Weekly Reports Recommendations and Reports, dated September 6, 1996, entitled, "Update: Vaccine Side Effects, Adverse Reactions, Contraindications and Precautions." Members of the public may obtain copies of the report by writing to MS Publications, C.S.P.O. Box 9120, Waltham, MA 02254, telephone 1-800-843-6356, 617-893-3800 (Massachusetts). The cost of the publication is \$4.00. It may be obtained without charge through use of the World-Wide Web (WWW). The address is "http://www.cdc.gov/epo/mmwr/mmwr-rr.html." As stated by the Secretary in the February 20, 1997, **Federal Register** (62 Fed. Reg. 7687), we have found that the ACIP recommendations are consistent with the findings that the Department made as part of section 313 NPRM (60 FR 56289, Nov. 8, 1995), and that they satisfy the statutory requirements for guidelines. Accordingly, we proposed that the ACIP recommendations will constitute the guidelines called for by section 313.

Section 313 calls for consultation with the Advisory Commission on Childhood Vaccines (ACCV) and notice and opportunity for public hearing with respect to these guidelines. The ACIP recommendations were submitted to the ACCV at its meeting of June 6-7, 1996.

The hearing will be held on September 11, 1997, beginning at 1:00 p.m., in Conference Rooms D and E in the Parklawn Building, 5600 Fishers Lane, Rockville, Maryland 20857. The hearing will be held following the noon adjournment of the September 10-11 meeting of the ACCV.

The presiding officer representing the Secretary of HHS, will be Mr. Thomas E. Balbier, Jr., Director, Division of Vaccine Injury Compensation, Bureau of Health Professions (BHP), Health Resources and Services Administration.

Persons who wish to participate are requested to file a notice of participation with the Department on or before August 28, 1997. The notice should be mailed to Division of Vaccine Injury Compensation, BHP, Room 8A-35, Parklawn Building, 5600 Fishers Lane, Rockville, Maryland 20857. To ensure timely handling, any outer envelope should be clearly marked "Guidelines." The notice of participation should contain the interested person's name, address, telephone number, any business or organizational affiliation of the person desiring to make a presentation, a brief summary of the presentation, and the approximate time requested for the presentation. Groups that have similar interests should consolidate their comments as part of one presentation. Time available for the hearing will be allocated among the persons who properly file notices of participation. If time permits, interested parties attending the hearing who did not submit a notice of participation in advance will be allowed to make an oral presentation at the conclusion of the hearing.

Persons who find that there is insufficient time to submit the required information in writing may give oral notice of participation by calling Mr. Thomas E. Balbier, Jr., Director, Division of Vaccine Injury Compensation, at (301) 443-6593 no later than August 28, 1997. Those persons who give oral notice of participation should also submit written notice containing the information described above to the Department by the close of business September 4, 1997.

After reviewing the notices of participation and accompanying information, the Department will schedule each appearance and notify each participant by mail or telephone of the time allotted to the person(s) and the approximate time the person's oral presentation is scheduled to begin.

Written comments and transcripts of the hearing will be made available for public inspection as soon as they have been prepared, on weekdays (Federal holidays excepted) between the hours of

8:30 a.m. and 5:00 p.m. at the Division of Vaccine Injury Compensation, Room 8A-35, Parklawn Building, 5600 Fishers Lane, Rockville, Maryland 20857.

Dated: July 14, 1997.

Claude Earl Fox,
Acting Administrator.

[FR Doc. 97-18908 Filed 7-17-97; 8:45 am]

BILLING CODE 4160-15-U

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Centers for Disease Control and Prevention

[Announcement Number 783]

Cooperative Agreements for Postdoctoral Fellowship Training Programs in Infectious Diseases

Introduction

The Centers for Disease Control and Prevention (CDC) announces the availability of fiscal year (FY) 1997 funds for cooperative agreements to provide assistance for Postdoctoral Fellowship Training Programs in Infectious Diseases.

CDC is committed to achieving the health promotion and disease prevention objectives of Healthy People 2000, a national activity to reduce morbidity and mortality and improve the quality of life. This announcement is related to the priority area of Immunization and Infectious Diseases. (For ordering a copy of Healthy People 2000, see the section **WHERE TO OBTAIN ADDITIONAL INFORMATION.**)

Authority

This program is authorized under Sections 301 (42 U.S.C. 241) and 317(k)(2) (42 U.S.C. 247b(k)(2)) of the Public Health Service Act, as amended.

Smoke-Free Workplace

CDC strongly encourages all grant recipients to provide a smoke-free workplace and to promote the nonuse of all tobacco products, and Pub. L. 103-227, the Pro-Children Act of 1994, prohibits smoking in certain facilities that receive Federal funds in which education, library, day care, health care, and early childhood development services are provided to children.

Eligible Applicants

Assistance will be provided only to university affiliated schools of medicine with infectious disease programs accredited by the Accreditation Council for Graduate Medical Education (ACGME). Applicants meeting this criteria are the most appropriate